A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19

Overview of attention for article published in Critical Care, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs: 1 blog
twitter: 2 X users

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 12 Mendeley

Summary Blogs X Wikipedia Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 55,603 followers.

A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 @Crit_Care | #ECM https://t.co/GwYkBItWUK

02 Aug 2022

Reply Repost Favourite

Angiotensin 1–7 (TXA-127) for the treatment of severe #COVID19 720 patients were assessed from February 09, 2021, to May 17, 2021, and after exclusion of 698 patients 22 participants 😮 were randomized Something wrong with this study? And published in CC

29 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.